Curative Biosciences Valuation
| CBDX Stock | USD 0.0001 0.00 0.00% |
Curative Biosciences seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Curative Biosciences from analyzing the firm fundamentals such as Return On Asset of -38.44, shares outstanding of 31.57 M, and EBITDA of (50.35 K) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Curative Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Curative Biosciences is based on 3 months time horizon. Increasing Curative Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Curative Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Curative Pink Sheet. However, Curative Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 |
The intrinsic value of Curative Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Curative Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Curative Biosciences helps investors to forecast how Curative pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Curative Biosciences more accurately as focusing exclusively on Curative Biosciences' fundamentals will not take into account other important factors: Curative Biosciences Total Value Analysis
Curative Biosciences is currently forecasted to have valuation of 9.68 M with market capitalization of 10.56 M, debt of 156.45 K, and cash on hands of 982. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Curative Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.68 M | 10.56 M | 156.45 K | 982 |
Curative Biosciences Asset Utilization
One of the ways to look at asset utilization of Curative is to check how much profit was generated for every dollar of assets it reports. Curative Biosciences shows a negative utilization of assets of -38.44 percent, losing $0.38 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Curative Biosciences shows how discouraging it operates for each dollar spent on its assets.Curative Biosciences Ownership Allocation
Curative Biosciences holds a total of 31.57 Million outstanding shares. Curative Biosciences shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 76.24 percent of Curative Biosciences outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Curative Biosciences Profitability Analysis
Net Loss for the year was (53.2 K) with profit before overhead, payroll, taxes, and interest of 0.About Curative Biosciences Valuation
Our relative valuation model uses a comparative analysis of Curative Biosciences. We calculate exposure to Curative Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Curative Biosciences's related companies.Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. Curative Biosciences, Inc. was founded in 2009 and is based in Miami, Florida. Curative Biosciences is traded on OTC Exchange in the United States.
8 Steps to conduct Curative Biosciences' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Curative Biosciences' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Curative Biosciences' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Curative Biosciences' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Curative Biosciences' revenue streams: Identify Curative Biosciences' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Curative Biosciences' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Curative Biosciences' growth potential: Evaluate Curative Biosciences' management, business model, and growth potential.
- Determine Curative Biosciences' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Curative Biosciences' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Curative Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 15.7 M | |
| Retained Earnings | -53.2 M |
Additional Tools for Curative Pink Sheet Analysis
When running Curative Biosciences' price analysis, check to measure Curative Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biosciences is operating at the current time. Most of Curative Biosciences' value examination focuses on studying past and present price action to predict the probability of Curative Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biosciences' price. Additionally, you may evaluate how the addition of Curative Biosciences to your portfolios can decrease your overall portfolio volatility.